MIA joins Sydney Health Partners

MIA joins Sydney Health Partners

22 December 2021

Melanoma Institute Australia (MIA) has joined Sydney Health Partners, becoming the 16th health organisation and 11th Medical Research Institute in the growing Partnership.

MIA is a nationally-affiliated network of melanoma researchers and clinicians based in Sydney at The Poche Centre– the world’s largest melanoma research and treatment facility.

The membership builds on MIA’s existing affiliations with four founding members of Sydney Health Partners - the University of Sydney, and Sydney, Northern Sydney and Western Sydney Local Health Districts.

Sydney Health Partners’ Executive Director, Professor Don Nutbeam, has welcomed MIA, saying “culturally there’s a great fit between Melanoma Institute Australia and what we are aspiring to achieve across the health system with our health partners.”  

“Like MIA, we seek a faster, better fit between the world class research that’s going on across all our Partners, the quality care we are looking to deliver to our patients and the public benefit that we are trying to deliver to wider society.”

 

Co-Medical Director of MIA, Professor Georgina Long AO, says Melanoma Institute Australia shares Sydney Health Partners’ focus on more rapidly translating research evidence into patient benefit.

“You can have great ideas, but you’ve got to test the ideas and ultimately, if the idea is worthwhile and impacts outcomes for patients then you’ve got to make sure that gets introduced to the rest of Australia and the rest of the world.”

According to MIA Co-Medical Director, Professor Richard Scolyer AO, it’s vital that MIA does more than just find answers to the clinical questions that arise when treating patients.

“We are the largest melanoma treatment centre in the world and because of that we see patterns and there are questions that come up that need to be addressed,” he said. “So, when we find answers to those questions, we are committed to implementing changes to get better outcomes for our patients.”

Professor Nutbeam says that while MIA will hopefully benefit from collaborating with a wider community of research translators, the Institute has just as much to offer the Partnership.

“I think that because of their track record and experience they have a fair bit to teach us about how to get this right and get the closest possible connection between outstanding research and great clinical care.”

Sydney Health Partners is accredited by the National Health and Medical Research Council as an Advanced Health Research and Translation Centre.

Commencing operations in 2016 with 14 members, the Partnership subsequently welcomed the Kolling Institute of Medical Research in 2019.

With the addition of Melanoma Institute Australia, Sydney Health Partners is now one of the largest academic health science centres in the world.

Collectively, the Partners provide care to 2.7 million people, representing more than 10 per cent of the Australian population.

Sydney Health Partners’ goal is to demonstrate that new evidence-based interventions can be successfully implemented and scaled-up in large and diverse health systems.

“Since Sydney Health Partners’ establishment, the health system’s need for better research translation has only become more obvious,” said Professor Nutbeam.

“So, we were really delighted when the MIA contacted us to become partners with Sydney Health Partners.

“They exemplify a lot of the things we are trying to get right in our health care system – outstanding world class research being connected to patient care as quickly and efficiently as possible.”

Professors Long and Scolyer describe joining Sydney Health Partners as “a fantastic opportunity to work with people with the breadth of experience, knowledge and skills to have those research findings implemented.”

“To make things happen you need policy, you need energy and you need advocacy – and that can only be done when you bring the right groups of people, with different skills sets, together.”

Read more about Sydney Health Partners here

Australia's oldest melanoma survivor steps up to save lives on his 105th birthday
11 Mar 2021

Australia's oldest melanoma survivor steps up to save lives on his 105th birthday

Melanoma research saved Bert's life at 101 and now he wants to give back. 

Tags: melanoma
Predicting disease spread in thin melanoma
05 Mar 2021

Predicting disease spread in thin melanoma

A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.   

Tags: melanoma
Exploring our own clinical questions through MIA's new trials initiative
04 Mar 2021

Exploring our own clinical questions through MIA's new trials initiative

MIA has recently established a new division of our Clinical Trials Program which co-ordinates and manages investigator-led multi-centre trials. 

Tags: melanoma
Young researchers awarded Fellowships to pursue innovative treatments for melanoma
04 Mar 2021

Young researchers awarded Fellowships to pursue innovative treatments for melanoma

Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.

Tags: melanoma
Young researchers receive boost to develop innovative treatment for melanoma
04 Mar 2021

Young researchers receive boost to develop innovative treatment for melanoma

Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.

Tags: melanoma
Melanoma March 2022
01 Mar - 31 Mar 2022

Melanoma March 2022

We are excited to announce a return to our much-loved physical Melanoma March events in March 2022!

Launch of Melanoma March 2021
01 Mar 2021

Launch of Melanoma March 2021

Aussies urged to leave their footprint on melanoma as efforts step up to save lives from the disease.

Tags: melanoma
Olivia Vivian announced as MIA ambassador
12 Feb 2021

Olivia Vivian announced as MIA ambassador

Olivia is using her Ninja star power to shine a spotlight on melanoma prevention - in memory of her dad. 

Tags: melanoma
Melanoma breakthrough - neoadjuvant treatment saving lives.
09 Feb 2021

Melanoma breakthrough - neoadjuvant treatment saving lives.

Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.

Tags: melanoma
Melanoma breakthrough - neoadjuvant therapy saving lives.
09 Feb 2021

Melanoma breakthrough - neoadjuvant therapy saving lives.

Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.

Tags: melanoma
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
04 Feb 2021

Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?

New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.

Tags: melanoma
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
04 Feb 2021

Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?

New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.

Tags: melanoma
A message to all Australians from melanoma patient Stuart Taylor
16 Dec 2020

A message to all Australians from melanoma patient Stuart Taylor

Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate. 

Tags: melanoma
Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
02 Dec 2020

Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.

A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.

Tags: melanoma
It's 'Game On Mole' this summer!
01 Dec 2020

It's 'Game On Mole' this summer!

All Australians are urged to join the fight against melanoma this summer. 

Tags: melanoma
Prof Richard Scolyer named Outstanding Cancer Researcher of the Year  
27 Nov 2020

Prof Richard Scolyer named Outstanding Cancer Researcher of the Year  

The ground-breaking work of MIA's Co-Medical Director Prof Richard Scolyer has been recognised with NSW’s highest accolade for cancer research. 

Tags: melanoma
Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award
24 Nov 2020

Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award

A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.

Tags: melanoma
MIA researchers feature on prestigious Highly Cited Researchers 2020 List
18 Nov 2020

MIA researchers feature on prestigious Highly Cited Researchers 2020 List

The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.

Tags: melanoma
Game On Mole is back this summer!
13 Nov 2020

Game On Mole is back this summer!

The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.

Tags: melanoma
RCPA recognition for Professor Richard Scolyer.
12 Nov 2020

RCPA recognition for Professor Richard Scolyer.

Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.

Tags: melanoma